|
LMTK2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.28770000054723E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.99059999994589E-06 |
| Normal-vs-Stage2 |
5.976700E-03 |
| Normal-vs-Stage3 |
4.27609999964496E-07 |
| Normal-vs-Stage4 |
1.78441999999501E-05 |
| Stage1-vs-Stage2 |
3.979000E-01 |
| Stage1-vs-Stage3 |
2.933400E-01 |
| Stage1-vs-Stage4 |
4.105600E-01 |
| Stage2-vs-Stage3 |
1.345770E-01 |
| Stage2-vs-Stage4 |
1.800980E-01 |
| Stage3-vs-Stage4 |
9.811000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.7647999968965E-08 |
| Normal-vs-AfricanAmerican |
6.369800E-02 |
| Normal-vs-Asian |
2.002000E-04 |
| Caucasian-vs-AfricanAmerican |
1.347430E-01 |
| Caucasian-vs-Asian |
9.810600E-01 |
| AfricanAmerican-vs-Asian |
2.193600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.38090000440161E-08 |
| Normal-vs-Female |
3.22139999997528E-06 |
| Male-vs-Female |
9.827700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.52850000000915E-05 |
| Normal-vs-Age(41-60Yrs) |
1.96050000011994E-07 |
| Normal-vs-Age(61-80Yrs) |
3.72250000000296E-05 |
| Normal-vs-Age(81-100Yrs) |
7.963900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.698240E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.644200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.447200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.564000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.913800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.585400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.033940E-02 |
| Classical-VS-Follicular |
5.207400E-01 |
| Classical-VS-Other |
1.310410E-01 |
| Classical-VS-Normal |
1.52180999999363E-05 |
| Tall-VS-Follicular |
1.007370E-01 |
| Tall-VS-Other |
5.394400E-01 |
| Tall-VS-Normal |
3.10080000009982E-07 |
| Follicular-VS-Other |
2.650000E-01 |
| Follicular-VS-Normal |
1.552920E-04 |
| Other-VS-Normal |
2.881000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.49360000004195E-06 |
| Normal-vs-N1 |
3.9913000000058E-05 |
| N0-vs-N1 |
5.067200E-01 |
|
|
